12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AM0010: Phase I started

Armo began a U.S. Phase I trial to evaluate once-daily AM0010 in 15-30 patients. Armo licensed exclusive, worldwide rights to...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >